{"DataElement":{"publicId":"58269","version":"3","preferredName":"Laboratory Procedure Bone Marrow HLA-DR Antigen Outcome Percentage Value","preferredDefinition":"bone marrow HLA-DR-positive cells, as a percentage of total nucleated marrow cells.","longName":"LAB_BM_HLA_OC_PTG_VA","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2189855","version":"1","preferredName":"Laboratory Procedure Bone Marrow HLA-DR Antigen Outcome","preferredDefinition":"the value, in percent, of the medical procedure that involves testing a sample of bone marrow (the soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets), for HLA-DR, encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini.","longName":"LAB_BM_HLADR_OC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2779794","version":"1","preferredName":"Bone Marrow HLA-DR Antigen Outcome","preferredDefinition":"The soft, sponge-like tissue in the center of bones that produces white blood cells, red blood cells, and platelets.:Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants. (NCI):Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C12431:C16692:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"HLA-DR Antigen","conceptCode":"C16692","definition":"Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56007672-E43C-265F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-09-03","modifiedBy":"ONEDATA","dateModified":"2008-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6429533-7D72-2F87-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2019101","version":"1","preferredName":"Blood Specimen Lab Percentage Value","preferredDefinition":"a percentage for a hematologic laboratory value.","longName":"HMT_LAB_PTG_VAL","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"5","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208119","version":"1","preferredName":"Percentage Value","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A numerical quantity measured or assigned or computed.","longName":"C25613:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3E46-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1E25A5E-97B6-3155-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-10-12","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-07-07","modifiedBy":"CAMPBELB","dateModified":"2008-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811957","version":"1","longName":"Labs","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811943","version":"1","longName":"Hodgkin's Lymphoma","context":"CTEP"},{"publicId":"2811944","version":"1","longName":"NonHodgkins Lymphoma","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Marrow HLA-DR-Positive Cells","type":"Preferred Question Text","description":"Marrow HLA-DR-Positive Cells (%)","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Bone Marrow, HLA-DR-Positive Cells, Percentage","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C41665AF-01CB-4DAB-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-04","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-08-04","modifiedBy":"REEVESD","dateModified":"2011-04-05","changeDescription":"ISO 11179 Compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}